title: CD133 expression: a potential prognostic marker for non-small cell lung cancers.
abstract: BACKGROUND
  CD133 is a membrane glycoprotein containing five transmembrane loops. Previous reports suggest that a CD133-positive subpopulation of multipotent cells with extensive proliferative and self-renewal characteristics has biological features of a cancer stem cell. In addition, the presence of CD133-positive cells was associated with a significantly poorer prognosis for some solid tumors, compared to those with CD133-negative cells. However, the clinicopathological significance of CD133 in non-small cell lung cancer (NSCLC) remains controversial.
  
  
  METHODS
  We conducted immunohistochemical assessment of 161 NSCLCs surgically resected at Hokkaido University Hospital between 1982 and 1994 to evaluate correlations between CD133 expression and various clinicopathological features.
  
  
  RESULTS
  CD133 expression was significantly correlated with pathological stages (pStages) II, III, and IV for the various NSCLC types analyzed and was an independent factor for unfavorable prognosis in this population (hazard ratio = 3.157, P = 0.015).
  
  
  CONCLUSIONS
  CD133 expression was correlated with pStage and was predictive of unfavorable prognosis in patients with pStages II, III, and IV NSCLC. These results suggest the possibility of using CD133 as a novel prognostic marker in these patients.
authors.affiliation: First Department of Medicine, Hokkaido University School of Medicine, North 15, West 7, Kita-ku, Sapporo, 060-8638, Japan.
authors.forename: Hidenori
authors.initials: H
authors.lastname: Mizugaki
authors.forename: Jun
authors.initials: J
authors.lastname: Sakakibara-Konishi
authors.forename: Junko
authors.initials: J
authors.lastname: Kikuchi
authors.forename: Jun
authors.initials: J
authors.lastname: Moriya
authors.forename: Kanako C
authors.initials: KC
authors.lastname: Hatanaka
authors.forename: Eiki
authors.initials: E
authors.lastname: Kikuchi
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kinoshita
authors.forename: Satoshi
authors.initials: S
authors.lastname: Oizumi
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Dosaka-Akita
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Matsuno
authors.forename: Masaharu
authors.initials: M
authors.lastname: Nishimura
mesh_terms: D000071916:AC133 Antigen; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry / Q000401:mortality* / Q000473:pathology; D005260:Female; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000737:chemistry / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010455:Peptides / Q000032:analysis*; D011379:Prognosis; D016016:Proportional Hazards Models
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides